NCE-based strategy for nuclear reprogramming and regenerative medicine
NCE-based strategy for nuclear reprogramming and regenerative medicine
批准号:
7941985
负责人:
JOHN P COOKE
金额:
$134.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-08-31
关键词:
AdultAdvisory CommitteesAnimalsApplied GeneticsBiological AssayBiomedical EngineeringCardiovascular systemCell ExtractsCell LineCell SurvivalCell physiologyCellsChemicalsChemistryClinicalClinical TrialsColoradoCommunitiesCore FacilityDNA IntegrationDevelopmentDoseEmbryoEndothelial CellsEngraftmentEnhancersEpigenetic ProcessEthical IssuesFibroblastsFoundationsFundingGenerationsGeneticHumanImmuneIn VitroInstitutesIntellectual PropertyKaryotype determination procedureKnowledgeLeadMethodologyMethodsMicrofluidicsMitochondriaMolecularMolecular AbnormalityMonitoring Clinical TrialsMusNuclearPenetrationPeptidesPhenotypePluripotent Stem CellsProductionProteinsProtocols documentationReagentRecruitment ActivityRegenerative MedicineReportingResearchResearch InstituteResearch PersonnelSafetySomatic CellSourceStem Cell ResearchStem cellsStimulusTeratomaTestingTherapeuticTimeTransformed Cell LineTranslationsUniversitiesValproic AcidWorkbasebiobankc-myc Genescell bankclinical applicationcomparative genomic hybridizationdesignhuman embryonic stem cellimprovedinsightnovelnovel strategiesnuclear reprogrammingpre-clinicalprofessorpublic health relevancesingle cell analysissmall moleculesmall molecule librariesstem cell biologytooltranslational medicineuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The discovery that a small set of reprogramming factors (e.g. Oct4, Sox2, Klf4 and c-Myc) can induce the nuclear reprogramming of adult human cells to pluripotentiality, is a landmark development in regenerative medicine. Although human induced pluripotential stem cells (hiPSCs) promise a source of therapeutic cells, without the ethical issues or immune barriers of human embryonic stem cells (ESCs), the use of DNA-based methods for generating human induced pluripotential cells (hiPSCs) may introduce genetic or epigenetic errors during nuclear reprogramming. To overcome these safety concerns and to increase the efficiency of generating safe and effective iPSC, we will discover and refine new chemical entities (NCE) that induce reprogramming or enhance its efficiency. These new chemical entities include small molecules derived from a unique chemical library together with novel cell-permeant peptides designed for effective nuclear entry. We anticipate that NCE-based nuclear reprogramming will avoid concerns associated with DNA-based approaches such as DNA integration, as well as slow, inefficient and aberrant reprogramming. The knowledge that is generated, and the tools that are derived from that knowledge, will be useful for many stem cell biologists and investigators in regenerative medicine. Our specific aims are: 1) To develop and refine reagents and protocols for an efficient NCE-based strategy of generating hiPSCs. We will characterize the reprogramming efficiency using small molecules and peptides. This approach will provide for unbiased cell uptake (by comparison to DNA-based strategies), and more precise control over the dose, duration and timing of the reprogramming stimuli. 2) To characterize the safety and function of these hiPSCs. We will apply the genetic, epigenetic and mitochondrial analyses to characterize iPSCs generated by the NCE-based approach. Especially, we will focus on the differentiation of human iPSC to endothelial cells (EC) and apply the same rigorous genetic, epigenetic and mitochondrial analyses, as well as lineage-specific functional assays, to document the fidelity of hiPSC-EC to the expected phenotype.
PUBLIC HEALTH RELEVANCE: This work will provide scientific insights, methodologies and reagents of utility for efficient nuclear reprogramming of human somatic cells into safe and effective hiPSCs for the entire regenerative medicine community.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip
-
批准号:10199360
-
项目类别:
-
资助金额:$72.16万
-
财政年份:2021
-
负责人:JOHN P COOKE
-
依托单位:
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip
-
批准号:10617651
-
项目类别:
-
资助金额:$73.23万
-
财政年份:2021
-
负责人:JOHN P COOKE
-
依托单位:
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip
-
批准号:10396569
-
项目类别:
-
资助金额:$66.53万
-
财政年份:2021
-
负责人:JOHN P COOKE
-
依托单位:
Reversal of Heart Failure: Role of Vascular Recovery
-
批准号:10215614
-
项目类别:
-
资助金额:$71.09万
-
财政年份:2020
-
负责人:JOHN P COOKE
-
依托单位:
Reversal of Heart Failure: Role of Vascular Recovery
-
批准号:10397100
-
项目类别:
-
资助金额:$71.09万
-
财政年份:2020
-
负责人:JOHN P COOKE
-
依托单位:
Reversal of Heart Failure: Role of Vascular Recovery
-
批准号:10602443
-
项目类别:
-
资助金额:$71.09万
-
财政年份:2020
-
负责人:JOHN P COOKE
-
依托单位:
Role of S-nitrosylation in Transdifferentiation
-
批准号:9906255
-
项目类别:
-
资助金额:$40.38万
-
财政年份:2018
-
负责人:JOHN P COOKE
-
依托单位:
Cell Characterization and Imaging for Regenerative Therapies in Ischemic Diseases
-
批准号:8288408
-
项目类别:
-
资助金额:$53.44万
-
财政年份:2012
-
负责人:JOHN P COOKE
-
依托单位:
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
-
批准号:8334482
-
项目类别:
-
资助金额:$40.52万
-
财政年份:2011
-
负责人:JOHN P COOKE
-
依托单位:
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
-
批准号:8733170
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2011
-
负责人:JOHN P COOKE
-
依托单位:
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
-
批准号:8529537
-
项目类别:
-
资助金额:$38.11万
-
财政年份:2011
-
负责人:JOHN P COOKE
-
依托单位:
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
-
批准号:8042144
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2011
-
负责人:JOHN P COOKE
-
依托单位:
Mechanisms in Innovation in Vascular Disease
-
批准号:7943313
-
项目类别:
-
资助金额:$11.93万
-
财政年份:2010
-
负责人:JOHN P COOKE
-
依托单位:
Mechanisms in Innovation in Vascular Disease
-
批准号:8294715
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2010
-
负责人:JOHN P COOKE
-
依托单位:
Mechanisms in Innovation in Vascular Disease
-
批准号:8109370
-
项目类别:
-
资助金额:$24.25万
-
财政年份:2010
-
负责人:JOHN P COOKE
-
依托单位:
Basic and Translational Research iPSC-based hematologic and vascular therapies
-
批准号:8279281
-
项目类别:
-
资助金额:$120.41万
-
财政年份:2009
-
负责人:JOHN P COOKE
-
依托单位:
Basic and Translational Research iPSC-based hematologic and vascular therapies
-
批准号:8471163
-
项目类别:
-
资助金额:$79.72万
-
财政年份:2009
-
负责人:JOHN P COOKE
-
依托单位:
Basic and Translational Research iPSC-based hematologic and vascular therapies
-
批准号:8307701
-
项目类别:
-
资助金额:$4.96万
-
财政年份:2009
-
负责人:JOHN P COOKE
-
依托单位:
Basic and Translational Research iPSC-based hematologic and vascular therapies
-
批准号:7939703
-
项目类别:
-
资助金额:$117.66万
-
财政年份:2009
-
负责人:JOHN P COOKE
-
依托单位:
Basic and Translational Research iPSC-based hematologic and vascular therapies
-
批准号:7833754
-
项目类别:
-
资助金额:$120.11万
-
财政年份:2009
-
负责人:JOHN P COOKE
-
依托单位:
海外基金